My Vision Test

MyVisionTest News Archive

Ontario second province to make Lucentis available to fight AMD
Ontarians suffering from the leading cause of blindness in Canada will now have access to the new prescription medicine Lucentis.

Neovascular (wet) age-related macular degeneration (AMD) is a degenerative condition affecting central vision in people typically aged fifty and older. Lucentis works to maintain and even improve vision affected by wet AMD.

Today's investment of over $100 million over three years means that Ontarians suffering from AMD will for the first time have access to this groundbreaking drug.

"The decision to cover Lucentis is fantastic news for the people of Ontario that suffer from macular degeneration," said Dr. Kyle Brydon, Chair of the Ontario Medical Association's Section on Ophthalmology. "Lucentis is one of the most effective treatments for people suffering from the wet form of macular degeneration...The government's decision to cover Lucentis will allow many more patients to be treated and potentially avoid the devastating impact of sudden, irreversible blindness."